From Symptoms to Systems: Investing in the Health of Women
For too long, the health of women has been reduced to a subcategory. Women’s biology shapes outcomes across every stage of life and every major disease area; yet research, diagnostics, and care pathways have not kept pace.
Women live longer than men, but spend more of those years in poor health. As workers, caregivers, and decision-makers, they drive the majority of healthcare utilization; the costs extend well beyond the individual.
Health2047’s thesis on the health of women targets that opportunity with capital and operational support for founders building durable, science-led solutions.
“The narrative that women's health is 'emerging' undermines decades of commercial activity.”
Warren Templeton
Managing Director, Health2047
If you are building science-led solutions that address the health of women across the lifespan, we want to hear from you.
Our process is deliberate and high-touch: we engage directly with the science, ask hard questions, and pair every portfolio company with a dedicated Health2047 champion who provides operational support alongside capital.
